RHO and chronic myelogenous leukemia, BCR-ABL1 positive: Traditionally, overactivation of the Rho GTPase pathways has been associated with malignancy, therefore, Rho/ROCK pathway inhibitors resulted in specific growth inhibition of CML cell line transformation (63).